RxDoctor Payments Data

Sean Haley, DO

Family Medicine · Canton, MANPI 1467612713

Payments from drug & device makers

$463in general payments, 2019–2025

Across 19 payments — averaging $24.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$281
  • Pfizer$67
  • Edwards Lifesciences$60
  • Exact Sciences$23
  • Novo Nordisk$20
  • AstraZeneca$13

What the payments were for

  • Food & beverage$463100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK11$281
Pfizer3$67
Edwards Lifesciences2$60
Exact Sciences1$23
Novo Nordisk1$20
AstraZeneca1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$463 in reported general payments places this provider in the 75th percentile of 1,049 family medicine providers in Massachusetts.

See all family medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$93,646
Medicare patients
232
Services billed
1,519

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban79$85,343
JardianceEmpagliflozin51$72,221
OzempicSemaglutide37$46,848
Xtampza ErOxycodone Myristate13$43,774
FarxigaDapagliflozin Propanediol27$27,898
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$21,018
TrulicityDulaglutide18$17,596
XareltoRivaroxaban17$16,069
JanuviaSitagliptin Phosphate11$13,424
SymbicortBudesonide/Formoterol Fumarate14$5,560
Atorvastatin Calcium385$4,744
Rosuvastatin Calcium150$4,006
ShingrixVaricella-Zoster Ge/As01b/Pf18$3,831
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$3,334
Metoprolol Succinate157$2,840

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$67$85,34379 claims
Novo NordiskOzempic$20$46,84837 claims
AstraZenecaFarxiga, Symbicort$13$33,45841 claims
GSKTrelegy Ellipta, Shingrix$281$24,85050 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,049 family medicine providers in Massachusetts.

Other family medicine in Canton

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →